Answers are grounded in this paper and cite their sources.
OBJECTIVE: This pilot study aims to demonstrate the feasibility of continuous sleep monitoring using the Withings Sleep Mat (WSM) and to illustrate Mean Disease Alleviation (MDA) as a potential metric for assessing real-world treatment effectiveness among patients with obstructive sleep apnea (OSA) treated with hypoglossal nerve stimulation (HGNS) or continuous positive airway pressure (CPAP). METHODS: Patients treated with CPAP or HGNS therapy were prospectively recruited. The WSM provided nightly estimations of sleep metrics including AHI, total sleep time, and other non-apneic metrics over 30- and 90-day periods. MDA integrating treatment efficacy and adjusted compliance was calculated as a composite measure of real-world treatment effectiveness. RESULTS: A total of 29 patients (mean age 59.8 years; 66% male; 93% White) were included, with 15 treated with CPAP and 14 with HGNS. The 90-day MDA, calculated using continuous AHI monitoring, was 36.05% for CPAP and 24.06% for HGNS (p = 0.20). Mean MDA using single-night sleep study (HGNS) or CPAP download (CPAP) was 81.72% (14.81) among CPAP patients and 51.18% (26.69) among HGNS patients (p = 0.002). HGNS patients experienced more awakenings (3.23 vs. 2.56, p = 0.031) and snoring episodes (2.86 vs. 1.79, p = 0.029) per night during the 30-day interval. CONCLUSION: This study demonstrates the feasibility of calculating MDA through continuous, non-invasive home monitoring using the WSA, offering a more comprehensive assessment of OSA treatment effectiveness than single-night studies alone. These findings support further evaluation of continuous home-based monitoring and integrated metrics like MDA to inform personalized therapy selection and long-term management.
No takes yet. Share an insight, caveat, or question.
Kaki et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: